• Conference Proceeding

COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN THE UNITED STATES [MEETING ABSTRACT PIN19]

Citation

Davis, A. E., Brogan, A. J., & Goodwin, B. B. (2016). COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN THE UNITED STATES [MEETING ABSTRACT PIN19]. Value in Health (ISPOR 21st Annual International Meeting), 19(3), A214-AA215.

Abstract

RAL has the lowest per-person cost compared with two other common first-line regimens, DRV/r and ATV/r, each used in combination with TDF/FTC, for treatment-naive adults with HIV-1 infection in the US. These results were found to be robust in sensitivity and scenario analyses. This economic evidence further complements the known clinical benefits of RAL as reported in the ACTG 5257 clinical trial.